Alcobra Ltd. (ADHD) Given Consensus Rating of “Hold” by Analysts
Shares of Alcobra Ltd. (NASDAQ:ADHD) have received an average rating of “Hold” from the ten research firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $1.55.
ADHD has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Alcobra from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a report on Tuesday, July 18th. Jefferies Group LLC restated a “hold” rating and issued a $1.25 price objective on shares of Alcobra in a report on Monday, June 12th. Finally, Roth Capital cut shares of Alcobra from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $4.00 to $1.00 in a report on Friday, September 29th.
COPYRIGHT VIOLATION NOTICE: “Alcobra Ltd. (ADHD) Given Consensus Rating of “Hold” by Analysts” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.watchlistnews.com/alcobra-ltd-adhd-given-consensus-rating-of-hold-by-analysts/1614351.html.
Alcobra (NASDAQ:ADHD) opened at 1.05 on Friday. The company has a 50-day moving average of $1.05 and a 200 day moving average of $1.11. Alcobra has a 12 month low of $0.83 and a 12 month high of $2.68. The company’s market cap is $28.94 million.
Alcobra (NASDAQ:ADHD) last announced its quarterly earnings data on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.02. On average, equities analysts forecast that Alcobra will post ($0.50) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Royce & Associates LP lifted its stake in shares of Alcobra by 15.5% in the first quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock worth $849,000 after buying an additional 100,000 shares in the last quarter. Citadel Advisors LLC lifted its stake in shares of Alcobra by 7,251.0% in the first quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock worth $114,000 after buying an additional 101,514 shares in the last quarter. Finally, Worth Venture Partners LLC lifted its stake in shares of Alcobra by 35.6% in the second quarter. Worth Venture Partners LLC now owns 271,982 shares of the biotechnology company’s stock worth $305,000 after buying an additional 71,465 shares in the last quarter. Hedge funds and other institutional investors own 29.68% of the company’s stock.
Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.